Company intelligence / Profile preview

InnoSkel

Nice, Provence-Alpes-Côte d'Azur, Franceorpha.net ↗

Ownership: Private
Development stage: Other

Overview

InnoSkel’s lead asset, INS101, a gene therapy targeting type II collagen disorders such as spondyloepiphyseal dysplasia congenita, has shown strong efficacy in preclinical proof-of-concept studies. The company was awarded an Innovation Passport by the UK MHRA to accelerate development and access for its first-in-class treatment. No clinical trial results are available yet.

Therapeutic areas: Rare Diseases
Modalities: Gene therapy
Industry: Biotech

Drug pipeline

1 asset

INS-101

Preclinical

Beyond the preview

Go deeper on InnoSkel.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on InnoSkel.

Explore the full profile